Clinical Trials Browser

Phase 2 × Terminated × Pharmacogenomic Variants × Clear all

NCT03506373 2026-03-05

Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia

Phase 2 Terminated

21 enrolled 11 charts

Waldenstrom Macroglobulinemia

NCT03557970 2021-12-02

JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia

Phase 2 Terminated

3 enrolled 10 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute